Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Alpha-synuclein aggregation.

Angela M Bodles¹, G Brent Irvine

¹University of Arkansas for Medical Sciences, Donald W. Reynolds Center on Aging, Little Rock, AR 72205, USA. Abodles@uams.edu

Protein and Peptide Letters

|June 9, 2004

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

α-Synuclein mRNA and soluble α-synuclein protein levels in post-mortem brain from patients with Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease.

Brain research·2012

Same author

Zinc transporter mRNA levels in Alzheimer's disease postmortem brain.

Journal of Alzheimer's disease : JAD·2012

Same author

BACE1 mRNA expression in Alzheimer's disease postmortem brain tissue.

Journal of Alzheimer's disease : JAD·2010

Same author

ZnT3 mRNA levels are reduced in Alzheimer's disease post-mortem brain.

Molecular neurodegeneration·2009

Same author

Variation in RTN3 and PPIL2 genes does not influence platelet membrane beta-secretase activity or susceptibility to alzheimer's disease in the northern Irish population.

Neuromolecular medicine·2009

Same author

A novel reciprocal and biphasic relationship between membrane cholesterol and beta-secretase activity in SH-SY5Y cells and in human platelets.

Journal of neurochemistry·2008

Same journal

Corrigendum to: Reviewing the Context of Molecular Modeling to Enhance the Application of Machine Learning Technologies for Safer Bioinformatics.

Protein and peptide letters·2026

Same journal

Corrigendum to: A Preliminary Study on the Antibacterial Activity of the Secretion of the Levantine Water Frog, <i>Pelophylax bedriagae</i> (Camerano, 1882) (Anura:Ranidae).

Protein and peptide letters·2026

Same journal

Potent Antioxidant and Antibacterial Activities of ≤3 kDa Hydrolyzed Sarcoplasmic Proteins from IPB-D1 Chicken.

Protein and peptide letters·2026

Same journal

Hybrid 3D Bioprinted Scaffolds for the Delivery of Peptide Therapeutics.

Protein and peptide letters·2026

Same journal

Targeting α-Synuclein: Current Strategies and Emerging Therapies for Synucleinopathies.

Protein and peptide letters·2026

Same journal

Biocompatible Excipients from Microalgae: Advancing Protein and Peptide Therapeutics through Sustainable Formulation Strategies.

Protein and peptide letters·2026

See all related articles

Researchers identified a key sequence in alpha-synuclein essential for its aggregation, a process linked to Parkinson's disease and dementia. This finding may lead to new inhibitors that block this aggregation pathway.

Area of Science:

Neuroscience
Biochemistry
Pathology

Background:

Alpha-synuclein is a core component of Lewy bodies, characteristic of Parkinson's disease.
Alpha-synuclein aggregation is implicated in the pathology of Parkinson's disease and other dementias.
Understanding the aggregation mechanism is crucial for developing therapeutic strategies.

Purpose of the Study:

To identify the specific region of alpha-synuclein critical for its aggregation.
To explore potential therapeutic targets for inhibiting alpha-synuclein aggregation.

Main Methods:

Peptide analysis of the NAC region of alpha-synuclein.
Investigating the aggregation properties of defined peptide sequences.

Main Results:

Related Experiment Videos

A specific sequence within the NAC region of alpha-synuclein was identified as necessary for aggregation.
This sequence represents a critical determinant of alpha-synuclein's fibrillar deposit formation.

Conclusions:

Targeting this essential aggregation sequence may offer a novel therapeutic approach.
Chemically modified analogues of this peptide could serve as inhibitors of alpha-synuclein aggregation.
This research provides a foundation for developing treatments for alpha-synucleinopathies.